How we treat oral chronic graft-versus-host disease

Blood

Volumn 120, Issue 17, 2012, Pages 3407-3418

  Treister, Nathaniel ^a,b   Duncan, Christine ^c,d   Cutler, Corey ^c,d   Lehmann, Leslie ^c,d  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

^b HARVARD SCHOOL OF DENTAL MEDICINE   (United States)

^c DANA FARBER CANCER INSTITUTE   (United States)

^d HARVARD MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BUDESONIDE; CEVIMELINE; CLOBETASOL; CLOBETASOL PROPIONATE; CORTICOSTEROID; DEXAMETHASONE; FLUCONAZOLE; FLUOCINONIDE; IMMUNOSUPPRESSIVE AGENT; NYSTATIN; PILOCARPINE; TACROLIMUS; TRIAMCINOLONE ACETONIDE;

APPLICATION SITE BURNING; ARTICLE; CHRONIC GRAFT VERSUS HOST DISEASE; CLINICAL FEATURE; DENTAL CARIES; DIFFERENTIAL DIAGNOSIS; DRUG BLOOD LEVEL; DRUG EFFICACY; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; INFECTIOUS COMPLICATION; LICHENOID; MOUTH DISEASE; MOUTH HYGIENE; MOUTH SQUAMOUS CELL CARCINOMA; MOUTH ULCER; MUCOCELE; ORAL CHRONIC GRAFT VERSUS HOST DISEASE; ORAL MUCOSAL DISEASE; PATIENT CARE; PRIORITY JOURNAL; SALIVARY GLAND DISEASE; SALIVATION; SCLEROSIS; SCREENING; SECONDARY INFECTION; SMOKING CESSATION; SOFT PALATE; SYMPTOM; THRUSH; TREATMENT DURATION; TREATMENT OUTCOME;

EID: 84868587829     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2012-05-393389     Document Type: Article

References (76)

1. Flowers ME, Lee S, Vogelsang G. An update on how to treat chronic GVHD. Blood. 2003;102(6):2312. (Pubitemid 37122417)
2. Kansu E. The pathophysiology of chronic graft-versus-host disease. Int J Hematol. 2004;79(3):209-215. (Pubitemid 38620767)
3. Lee SJ, Kim HT, Ho VT, et al. Quality of life associated with acute and chronic graft-versus-host disease. Bone Marrow Transplant. 2006;38(4):305-310. (Pubitemid 44203780)
4. Cutler CW, Jotwani R. Dendritic cells at the oral mucosal interface. J Dent Res. 2006;85(8):678-689. (Pubitemid 44297321)
5. Novak N, Gros E, Bieber T, Allam JP. Human skin and oral mucosal dendritic cells as 'good guys' and 'bad guys' in allergic immune responses. Clin Exp Immunol. 2010;161(1):28-33.
6. Flowers ME, Parker PM, Johnston LJ, et al. Comparison of chronic graft-versus-host disease after transplantation of peripheral blood stem cells versus bone marrow in allogeneic recipients: long-term follow-up of a randomized trial. Blood. 2002;100(2):415-419. (Pubitemid 34761101)
7. Hull KM, Kerridge I, Schifter M. Long-term oral complications of allogeneic haematopoietic SCT. Bone Marrow Transplant. 2012;47(2):265-270.
8. Imanguli MM, Alevizos I, Brown R, Pavletic SZ, Atkinson JC. Oral graft-versus-host disease. Oral Dis. 2008;14(5):396-412. (Pubitemid 351841727)
9. Arai S, Jagasia M, Storer B, et al. Global and organ-specific chronic graft-versus-host disease severity according to the 2005 NIH Consensus Criteria. Blood. 2011;118(15):4242-4249.
10. Baird K, Cooke K, Schultz KR. Chronic graft-versus-host disease (GVHD) in children. Pediatr Clin North Am. 2010;57(1):297-322.
11. Jacobsohn DA. Optimal management of chronic graft-versus-host disease in children. Br J Haematol. 2010;150(3):278-292.
12. Flowers ME, Inamoto Y, Carpenter PA, et al. Comparative analysis of risk factors for acute graft-versus-host disease and for chronic graft-versus-host disease according to National Institutes of Health consensus criteria. Blood. 2011;117(11):3214-3219.
13. Treister NS, Cook EF Jr, Antin J, Lee SJ, Soiffer R, Woo SB. Clinical evaluation of oral chronic graft-versus-host disease. Biol Blood Marrow Transplant. 2008;14(1):110-115. (Pubitemid 350286745)
14. Schubert MM, Correa ME. Oral graft-versus-host disease. Dent Clin North Am. 2008;52(1):79-109.
15. Singhal S, Powles R, Treleaven J, Rattenbury H, Mehta J. Pilocarpine hydrochloride for symptomatic relief of xerostomia due to chronic graft-versus-host disease or total-body irradiation after bone-marrow transplantation for hematologic malignancies. Leuk Lymphoma. 1997;24(5):539-543. (Pubitemid 27182209)
16. Imanguli MM, Atkinson JC, Mitchell SA, et al. Salivary gland involvement in chronic graft-versus-host disease: prevalence, clinical significance, and recommendations for evaluation. Biol Blood Marrow Transplant. 2010;16(10):1362-1369.
17. Kaufman E, Lamster IB. The diagnostic applications of saliva: a review. Crit Rev Oral Biol Med. 2002;13(2):197-212.
18. Fox PC, Busch KA, Baum BJ. Subjective reports of xerostomia and objective measures of salivary gland performance. J Am Dent Assoc. 1987;115(4):581-584.
19. Pai S, Ghezzi EM, Ship JA. Development of a Visual Analogue Scale questionnaire for subjective assessment of salivary dysfunction. Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 2001;91(3):311-316. (Pubitemid 33608850)
20. Chen A, Wai Y, Lee L, Lake S, Woo S. Using the modified Schirmer test to measure mouth dryness: a preliminary study. J Am Dent Assoc. 2005;136(2):164-170. (Pubitemid 40321224)
21. Balasubramaniam R, Alawi F, DeRossi S. Superficial mucoceles in chronic graft-versus-host disease: a case report and review of the literature. Gen Dent. 2009;57(1):82-88.
22. Palmason S, Marty FM, Treister NS. How do we manage oral infections in allogeneic stem cell transplantation and other severely immunocompromised patients? Oral Maxillofac Surg Clin North Am. 2011;23(4):579-599.
23. van Gelder T, ter Meulen CG, Hene R, Weimar W, Hoitsma A. Oral ulcers in kidney transplant recipients treated with sirolimus and mycophenolate mofetil. Transplantation. 2003;75(6):788-791. (Pubitemid 36373448)
24. Al-Mohaya M, Treister N, Al-Khadra O, Lehmann L, Padwa B, Woo SB. Calcineurin inhibitor-associated oral inflammatory polyps after transplantation. J Oral Pathol Med. 2007;36(9):570-574. (Pubitemid 47390144)
25. Shahrabi Farahani S, Treister NS, Khan Z, Woo SB. Oral verruciform xanthoma associated with chronic graft-versus-host disease: a report of five cases and a review of the literature. Head Neck Pathol. 2011;5(2):193-198.
26. Curtis RE, Rowlings PA, Deeg HJ, et al. Solid cancers after bone marrow transplantation. N Engl J Med. 1997;336(13):897-904. (Pubitemid 27137189)
27. Socie G, Curtis RE, Deeg HJ, et al. New malignant diseases after allogeneic marrow transplantation for childhood acute leukemia. J Clin Oncol. 2000;18(2):348-357. (Pubitemid 30056424)
28. Curtis RE, Metayer C, Rizzo JD, et al. Impact of chronic GVHD therapy on the development of squamous-cell cancers after hematopoietic stem-cell transplantation: an international case-control study. Blood. 2005;105(10):3802-3811. (Pubitemid 40662691)
29. Mawardi H, Elad S, Correa ME, et al. Oral epithelial dysplasia and squamous cell carcinoma following allogeneic hematopoietic stem cell transplantation: clinical presentation and treatment outcomes. Bone Marrow Transplant. 2011;46(6):884-891.
30. Filipovich AH, Weisdorf D, Pavletic S, et al. National Institutes of Health consensus development project on criteria for clinical trials in chronic graft-versus-host disease: I. Diagnosis and staging working group report. Biol Blood Marrow Transplant. 2005;11(12):945-956. (Pubitemid 41754712)
31. Shulman HM, Kleiner D, Lee SJ, et al. Histopathologic diagnosis of chronic graft-versus-host disease: National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus-Host Disease: II. Pathology Working Group Report. Biol Blood Marrow Transplant. 2006;12(1):31-47. (Pubitemid 43034096)
32. Koc S, Leisenring W, Flowers ME, et al. Therapy for chronic graft-versus-host disease: a randomized trial comparing cyclosporine plus prednisone versus prednisone alone. Blood. 2002;100(1):48-51. (Pubitemid 35177427)
33. Couriel D, Carpenter PA, Cutler C, et al. Ancillary therapy and supportive care of chronic graft-versus-host disease: National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-Versus-Host Disease: V. Ancillary Therapy and Supportive Care Working Group Report. Biol Blood Marrow Transplant. 2006;12(4):375-396. (Pubitemid 43380955)
34. Gonzalez-Moles MA, Scully C. Vesiculo-erosive oral mucosal disease: management with topical corticosteroids: 1. Fundamental principles and specific agents available. J Dent Res. 2005;84(4):294-301. (Pubitemid 43822008)
35. Sankar V, Hearnden V, Hull K, et al. Local drug delivery for oral mucosal diseases: challenges and opportunities. Oral Dis. 2011;17(Suppl 1):73-84.
36. Epstein JB, Reece DE. Topical cyclosporin A for treatment of oral chronic graft-versus-host disease. Bone Marrow Transplant. 1994;13(1):81-86. (Pubitemid 24052271)
37. Epstein JB, Nantel S, Sheoltch SM. Topical azathioprine in the combined treatment of chronic oral graft-versus-host disease. Bone Marrow Transplant. 2000;25(6):683-687. (Pubitemid 30156598)
38. Elad S, Or R, Garfunkel AA, Shapira MY. Budesonide: a novel treatment for oral chronic graft versus host disease. Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 2003;95(3):308-311. (Pubitemid 36877336)
39. Imanguli MM, Pavletic SZ, Guadagnini JP, Brahim JS, Atkinson JC. Chronic graft versus host disease of oral mucosa: review of available therapies. Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 2006;101(2):175-183. (Pubitemid 43163216)
40. Sari I, Altuntas F, Kocyigit I, et al. The effect of budesonide mouthwash on oral chronic graft versus host disease. Am J Hematol. 2007;82(5):349-356. (Pubitemid 46651137)
41. Mawardi H, Stevenson K, Gokani B, Soiffer R, Treister N. Combined topical dexamethasone/tacrolimus therapy for management of oral chronic GVHD. Bone Marrow Transplant. 2010;45:1062-1067.
42. Elad S, Zeevi I, Finke J, et al. Improvement in oral chronic graft-versus-host disease with the administration of effervescent tablets of topical budesonide: an open, randomized, multicenter study. Biol Blood Marrow Transplant. 2012;18:134-140.
43. Gonzalez-Moles MA, Morales P, Rodriguez-Archilla A, Isabel IR, Gonzalez-Moles S. Treatment of severe chronic oral erosive lesions with clobetasol propionate in aqueous solution. Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 2002;93(3):264-270. (Pubitemid 41124681)
44. Sanchez AR, Sheridan PJ, Rogers RS. Successful treatment of oral lichen planus-like chronic graft-versus-host disease with topical tacrolimus: a case report. J Periodontol. 2004;75(4):613-619. (Pubitemid 38635033)
45. Eckardt A, Starke O, Stadler M, Reuter C, Hertenstein B. Severe oral chronic graft-versus-host disease following allogeneic bone marrow transplantation: highly effective treatment with topical tacrolimus. Oral Oncol. 2004;40(8):811-814. (Pubitemid 39061097)
46. Albert MH, Becker B, Schuster FR, et al. Oral graft vs. host disease in children: treatment with topical tacrolimus ointment. Pediatr Transplant. 2007;11(3):306-311. (Pubitemid 46570150)
47. Elefante A, Muindi J, West K, et al. Long-term stability of a patient-convenient 1 mg/ml suspension of tacrolimus for accurate maintenance of stable therapeutic levels. Bone Marrow Transplant. 2006;37(8):781-784.
48. Fricain JC, Sibaud V, Swetyenga N, Tabrizi R, Campana F, Taieb A. Long-term efficacy of topical tacrolimus on oral lesions of chronic graft-versus-host disease. Br J Dermatol. 2007;156(3):588-590.
49. Conrotto D, Carrozzo M, Ubertalli AV, et al. Dramatic increase of tacrolimus plasma concentration during topical treatment for oral graft-versus-host disease. Transplantation. 2006;82(8):1113-1115. (Pubitemid 44632132)
50. Prot-Labarthe S, Therrien R, Champagne MA, Duval M, Joubert C. Toxic serum levels of tacrolimus after topical administration in an infant with severe cutaneous graft-versus-host disease. Bone Marrow Transplant. 2007;40(3):295-296. (Pubitemid 47108478)
51. Enk CD, Elad S, Vexler A, Kapelushnik J, Gorodetsky R, Kirschbaum M. Chronic graft-versus-host disease treated with UVB phototherapy. Bone Marrow Transplant. 1998;22(12):1179-1183. (Pubitemid 29021127)
52. Wolff D, Anders V, Corio R, et al. Oral PUVA and topical steroids for treatment of oral manifestations of chronic graft-vs.-host disease. Photodermatol Photoimmunol Photomed. 2004;20(4):184-190. (Pubitemid 39077014)
53. Greinix HT, van Besien K, Elmaagacli AH, et al. Progressive improvement in cutaneous and extracutaneous chronic graft-versus-host disease after a 24-week course of extracorporeal photopheresis-results of a crossover randomized study. Biol Blood Marrow Transplant. 2011;17(12):1775-1782.
54. Singhal S, Mehta J, Rattenbury H, Treleaven J, Powles R. Oral pilocarpine hydrochloride for the treatment of refractory xerostomia associated with chronic graft-versus-host disease. Blood. 1995;85(4):1147-1148.
55. Nagler RM, Nagler A. Pilocarpine hydrochloride relieves xerostomia in chronic graft-versus-host disease: a sialometrical study. Bone Marrow Transplant. 1999;23(10):1007-1011. (Pubitemid 29250845)
56. Nagler RM, Nagler A. The effect of pilocarpine on salivary constituents in patients with chronic graft-versus-host disease. Arch Oral Biol. 2001;46(8):689-695. (Pubitemid 32587802)
57. Carpenter PA, Schubert MM, Flowers ME. Cevimeline reduced mouth dryness and increased salivary flow in patients with xerostomia complicating chronic graft-versus-host disease. Biol Blood Marrow Transplant. 2006;12(7):792-794. (Pubitemid 43899415)
58. Agha-Hosseini F, Mirzaii-Dizgah I, Ghavamzadeh L, Ghavamzadeh A, Tohidast-Acrad Z. Effect of pilocarpine hydrochloride on unstimulated whole saliva flow rate and composition in patients with chronic graft-versus-host disease (cGVHD). Bone Marrow Transplant. 2007;39(7):431-434. (Pubitemid 46487309)
59. Nagler RM, Nagler A. Sialometrical and sialochemical analysis of patients with chronic graft-versus-host disease: a prolonged study. Cancer Invest. 2003;21(1):34-40. (Pubitemid 36292505)
60. Melchers LJ, Van Weert E, Beurskens CH, et al. Exercise adherence in patients with trismus due to head and neck oncology: a qualitative study into the use of the Therabite. Int J Oral Maxillofac Surg. 2009;38(9):947-954.
61. Stubblefield MD, Manfield L, Riedel ER. A preliminary report on the efficacy of a dynamic jaw opening device (dynasplint trismus system) as part of the multimodal treatment of trismus in patients with head and neck cancer. Arch Phys Med Rehabil. 2010;91(8):1278-1282.
62. Majorana A, Schubert MM, Porta F, Ugazio AG, Sapelli PL. Oral complications of pediatric hematopoietic cell transplantation: diagnosis and management. Support Care Cancer. 2000;8(5):353-365. (Pubitemid 30650519)
63. Hong CH, daFonseca M. Considerations in the pediatric population with cancer. Dent Clin North Am. 2008;52(1):155-181.
64. Treister NS, Woo SB, O'Holleran EW, Lehmann LE, Parsons SK, Guinan EC. Oral chronic graft-versushost disease in pediatric patients after hematopoietic stem cell transplantation. Biol Blood Marrow Transplant. 2005;11(9):721-731. (Pubitemid 41194981)
65. Heimdahl A, Johnson G, Danielsson KH, Lonqvist B, Sundelin P, Ringden O. Oral condition of patients with leukemia and severe aplastic anemia: follow-up 1 year after bone marrow transplantation. Oral Surg Oral Med Oral Pathol. 1985;60(5):498-504. (Pubitemid 16214417)
66. Curtis JW Jr, Caughman GB. An apparent unusual relationship between rampant caries and the oral mucosal manifestations of chronic graft-versus-host disease. Oral Surg Oral Med Oral Pathol. 1994;78(2):267-272.
67. Castellarin P, Stevenson K, Biasotto M, Yuan A, Woo SB, Treister NS. Extensive dental caries in patients with oral chronic graft-versus-host disease [published online ahead of print April 16, 2012]. Biol Blood Marrow Transplant. doi: 10.1016/j.bbmt.2012.04.009.
68. Tavss EA, Bonta CY, Joziak MT, Fisher SW, Campbell SK. High-potency sodium fluoride: a literature review. Compend Contin Educ Dent. 1997;18(2):31-36.
69. Marinho VC. Evidence-based effectiveness of topical fluorides. Adv Dent Res. 2008;20:3-7.
70. Cochrane NJ, Cai F, Huq NL, Burrow MF, Reynolds EC. New approaches to enhanced remineralization of tooth enamel. J Dent Res. 2010;89(11):1187-1197.
71. Spak CJ, Johnson G, Ekstrand J. Caries incidence, salivary flow rate and efficacy of fluoride gel treatment in irradiated patients. Caries Res. 1994;28(5):388-393.
72. Rosenberg PS, Greene MH, Alter BP. Cancer incidence in persons with Fanconi anemia. Blood. 2003;101(3):822-826. (Pubitemid 36139345)
73. Alter BP. Cancer in Fanconi anemia, 1927-2001. Cancer. 2003;97(2):425-440. (Pubitemid 36133810)
74. Alter BP, Giri N, Savage SA, et al. Malignancies and survival patterns in the National Cancer Institute inherited bone marrow failure syndromes cohort study. Br J Haematol. 2010;150(2):179-188.
75. Alter BP, Giri N, Savage SA, Rosenberg PS. Cancer in dyskeratosis congenita. Blood. 2009;113(26):6549-6557.
76. Lingen MW, Kalmar JR, Karrison T, Speight PM. Critical evaluation of diagnostic aids for the detection of oral cancer. Oral Oncol. 2008;44(1):10-22. (Pubitemid 350258631)